| BEONE-MEDICINES-LTD |
BEONE-MEDICINES-LTD |
92%
|
Under the BeOne Agreement, the Company is eligible to receive tiered royalties of mid-single to mid-double digit percentages on annual net sales of Ziihera in Asia (other than Japan), Australia and N… |
| JAZZ-PHARMACEUTICALS-IRELAND-LIMITED |
JAZZ-PHARMACEUTICALS-IRELAND-LIMITED |
92%
|
Under the BeOne Agreement, the Company is eligible to receive tiered royalties of mid-single to mid-double digit percentages on annual net sales of Ziihera in Asia (other than Japan), Australia and N… |
| DAIICHI-SANKYO |
DAIICHI-SANKYO |
90%
|
The decrease in total revenue was driven mainly by the achievement of non-recurring clinical milestone payments in 2025 of $14.0 million and $3.1 million from GSK and Daiichi Sankyo, respectively |
| BMY |
Bristol-Myers Squibb Company |
85%
|
Reciprocal relationship from BMY graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMY graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMY grap… |
| BMY |
Bristol-Myers Squibb Company |
85%
|
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w… |
| BMYMP |
Bristol-Myers Squibb Co |
85%
|
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w… |
| BMYMP |
Bristol-Myers Squibb Co |
85%
|
Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ZYME graph: Reciprocal relationship from BMYM… |
| CELGENE-ALPINE-INVESTMENT-CO-LLC |
CELGENE-ALPINE-INVESTMENT-CO-LLC |
85%
|
payments and royalties on potential future product sales we may receive. Importantly, these partnerships include predominantly non-target-exclusive licenses for any of our therapeutic platforms, so w… |
| JAZZ |
Jazz Pharmaceuticals plc |
85%
|
Reciprocal relationship from JAZZ graph: Reciprocal relationship from ZYME graph: : $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 3… |
| JAZZ |
Jazz Pharmaceuticals plc |
85%
|
: $ , 2022: $ ) in research and development expense and general and administrative expense accounts. As of December 31, 2024, the total amount contributed by ESPP participants and not yet settled is … |
| BEONE |
BEONE |
80%
|
These decreases were partially offset by higher royalty revenue from Jazz and BeOne in 2026 |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from ZYME graph: ne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): Milestone revenue Recognition of deferred revenue Dru… |
| JNJ |
Johnson & Johnson |
72%
|
ne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): Milestone revenue Recognition of deferred revenue Drug supply Development support payments Royalties Johnson & Johnson Innovative Medi… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from ZYME graph: our partnered product candidates, one or more of our U.S. patents may be eligible for limited patent term extension … |
| SNYNF |
Sanofi |
72%
|
our partnered product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term… |
| BEIGENE-LTD |
BEIGENE-LTD |
62%
|
and administrative support, as well as by raising capital, conducting business planning and protecting our intellectual property. Other than the receipt of royalties on sales of zanidatamab and regul… |
| CATALYST-PHARMS-INC |
CATALYST-PHARMS-INC |
62%
|
ock. Risks Relating to Our Partnerships We depend on our collaborative relationships with Jazz, BeOne and J&J to further develop and commercialize zanidatamab and other product candidates, and if our… |
| DAIICHI-SANKYO-CO-LTD |
DAIICHI-SANKYO-CO-LTD |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| DOHME-RESEARCH-GMBH |
DOHME-RESEARCH-GMBH |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-DEVELOPMEN |
GLAXOSMITHKLINE-INTELLECTUAL-PROPERTY-DEVELOPMEN |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| GSK |
GSK plc |
62%
|
Reciprocal relationship from GSK graph: Reciprocal relationship from ZYME graph: he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatme… |
| PROTECT-TUMOR-SPECIFIC-IMMUNE-CO |
PROTECT-TUMOR-SPECIFIC-IMMUNE-CO |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC |
ROYALTY-PHARMA-DEVELOPMENT-FUNDING-LLC |
62%
|
he China National Medical Products Administration (“NMPA”) to seek approval for zanidatamab for the first-line treatment for HER2+ locally advanced or metastatic GEA, including cancers of the stomach… |
| USA-LLC |
USA-LLC |
62%
|
tents Results of Operations for the Three Months Ended March 31, 2026 and 2025 Revenue Three Months Ended March 31, Increase/ (Decrease) (dollars in millions) 2026 2025 Revenue from research and deve… |
